Sara Ragazzini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sara Ragazzini has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Giacomo Bernava
University of Padua
3 shared publications - Gualtiero Ivanoe Colombo
Centro Cardiologico Monzino, IRCCS, Milan, Italy
3 shared publications - Maurizio Pesce
Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy
3 shared publications Franca Scocozza
Department of Civil Engineering and Architecture, University of Pavia, Pavia, Italy
2 shared publications- Gloria Garoffolo
Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, 20138 Milan, Italy
2 shared publications Michele Conti
Department of Civil Engineering and Architecture, University of Pavia, Pavia, Italy
2 shared publications
Latest Publications
- 31 August 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 152, 300-312
Mechanosensor YAP cooperates with TGF-β1 signaling to promote myofibroblast activation and matrix stiffening in a 3D model of human cardiac fibrosis
- 31 August 2022
- Published by Elsevier in Acta Biomaterialia
- Vol. 152, 300-312
Mechanosensor YAP cooperates with TGF-β1 signaling to promote myofibroblast activation and matrix stiffening in a 3D model of human cardiac fibrosis
- 22 July 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (3) , 239-257
Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation
Background: Conversion of cardiac stromal cells into myofibroblasts is typically associated with hypoxia conditions, metabolic insults, and/or inflammation, all of which are predisposing factors to cardiac fibrosis and heart failure. We hypothesized that this conversion could be also mediated by response of these cells to mechanical cues through activation of the Hippo transcriptional pathway. The objective of the present study was to assess the role of cellular/nuclear straining forces acting in myofibroblast differentiation of cardiac stromal cells under the control of YAP (yes-associated protein) transcription factor and to validate this finding using a pharmacological agent that interferes with the interactions of the YAP/TAZ (transcriptional coactivator with PDZ-binding motif) complex with their cognate transcription factors TEADs (TEA domain transcription factors), under high-strain and profibrotic stimulation. Methods: We employed high content imaging, 2-dimensional/3-dimensional culture, atomic force microscopy mapping, and molecular methods to prove the role of cell/nuclear straining in YAP-dependent fibrotic programming in a mouse model of ischemia-dependent cardiac fibrosis and in human-derived primitive cardiac stromal cells. We also tested treatment of cells with Verteporfin, a drug known to prevent the association of the YAP/TAZ complex with their cognate transcription factors TEADs. Results: Our experiments suggested that pharmacologically targeting the YAP-dependent pathway overrides the profibrotic activation of cardiac stromal cells by mechanical cues in vitro, and that this occurs even in the presence of profibrotic signaling mediated by TGF-β1 (transforming growth factor beta-1). In vivo administration of Verteporfin in mice with permanent cardiac ischemia reduced significantly fibrosis and morphometric remodeling but did not improve cardiac performance. Conclusions: Our study indicates that preventing molecular translation of mechanical cues in cardiac stromal cells reduces the impact of cardiac maladaptive remodeling with a positive effect on fibrosis.
- 22 July 2022
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 131 (3) , 239-257
Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation
Background: Conversion of cardiac stromal cells into myofibroblasts is typically associated with hypoxia conditions, metabolic insults, and/or inflammation, all of which are predisposing factors to cardiac fibrosis and heart failure. We hypothesized that this conversion could be also mediated by response of these cells to mechanical cues through activation of the Hippo transcriptional pathway. The objective of the present study was to assess the role of cellular/nuclear straining forces acting in myofibroblast differentiation of cardiac stromal cells under the control of YAP (yes-associated protein) transcription factor and to validate this finding using a pharmacological agent that interferes with the interactions of the YAP/TAZ (transcriptional coactivator with PDZ-binding motif) complex with their cognate transcription factors TEADs (TEA domain transcription factors), under high-strain and profibrotic stimulation. Methods: We employed high content imaging, 2-dimensional/3-dimensional culture, atomic force microscopy mapping, and molecular methods to prove the role of cell/nuclear straining in YAP-dependent fibrotic programming in a mouse model of ischemia-dependent cardiac fibrosis and in human-derived primitive cardiac stromal cells. We also tested treatment of cells with Verteporfin, a drug known to prevent the association of the YAP/TAZ complex with their cognate transcription factors TEADs. Results: Our experiments suggested that pharmacologically targeting the YAP-dependent pathway overrides the profibrotic activation of cardiac stromal cells by mechanical cues in vitro, and that this occurs even in the presence of profibrotic signaling mediated by TGF-β1 (transforming growth factor beta-1). In vivo administration of Verteporfin in mice with permanent cardiac ischemia reduced significantly fibrosis and morphometric remodeling but did not improve cardiac performance. Conclusions: Our study indicates that preventing molecular translation of mechanical cues in cardiac stromal cells reduces the impact of cardiac maladaptive remodeling with a positive effect on fibrosis.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Mechanosensor YAP Cooperates with TGF-Β1 Signaling to Promote Myofibroblast Differentiation and Matrix Stiffening in a 3d Model of Human Cardiac Fibrosis
Cardiac fibrosis is characterized by a maladaptive remodeling of the myocardium, which is controlled by various inflammatory pathways and cytokines. This remodeling is accompanied by a significant stiffening of the matrix, which may contribute to further activate collagen synthesis and scar formation. Evidence suggests that TGF-β1 signaling, the main pro-fibrotic pathway in cardiac fibrosis, might cooperates with the Hippo transcriptional pathway by activating YAP/TAZ. To directly test the cooperation of mechanical cues and paracrine signaling in cardiac fibrosis, we developed a 3D model of cardiac extracellular matrix remodeling by generating tissue blocks with Gelatin Methacrylate, a bioink with tunable stiffness, and human cardiosphere-derived stromal cells. Using this strategy, we assessed the cooperation of TGF-β1 and YAP/TAZ transcriptional complex to matrix compaction. Using mechanical compression tests, Masson’s trichrome staining, immunofluorescence, and RT-qPCR, we demonstrate that pharmacological inhibition of YAP/TAZ complex reverts almost completely the pro-compaction phenotype and the matrix-remodeling activity of cells treated with TGF-β1. Our data show a direct connection between the classical pro-fibrotic signaling driven by TGF-β1 and the mechanically activated pathways under the control of YAP/TAZ in cardiac remodeling. Treatment with the elective drug targeting YAP/TAZ is sufficient to override this cooperation with potential benefits for anti-fibrotic therapeutic applications. Funding Information: This work was supported by Institutional grants (Ricerca Corrente, 5 per 1000) issued by the Italian Ministry of Health to M.P. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: The use of human cardiac stromal cells was performed after authorization by the local ethical committee at Centro Cardiologico Monzino (approval date: 19 May 2012 and subsequent renewal on 16 May 2016) and have been performed in compliance with the Declaration of Helsinki. Patients signed an informed consent authorizing the donation of small fragments of cardiac tissue for research scopes.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessMechanosensor YAP Cooperates with TGF-Β1 Signaling to Promote Myofibroblast Differentiation and Matrix Stiffening in a 3d Model of Human Cardiac Fibrosis
Cardiac fibrosis is characterized by a maladaptive remodeling of the myocardium, which is controlled by various inflammatory pathways and cytokines. This remodeling is accompanied by a significant stiffening of the matrix, which may contribute to further activate collagen synthesis and scar formation. Evidence suggests that TGF-β1 signaling, the main pro-fibrotic pathway in cardiac fibrosis, might cooperates with the Hippo transcriptional pathway by activating YAP/TAZ. To directly test the cooperation of mechanical cues and paracrine signaling in cardiac fibrosis, we developed a 3D model of cardiac extracellular matrix remodeling by generating tissue blocks with Gelatin Methacrylate, a bioink with tunable stiffness, and human cardiosphere-derived stromal cells. Using this strategy, we assessed the cooperation of TGF-β1 and YAP/TAZ transcriptional complex to matrix compaction. Using mechanical compression tests, Masson’s trichrome staining, immunofluorescence, and RT-qPCR, we demonstrate that pharmacological inhibition of YAP/TAZ complex reverts almost completely the pro-compaction phenotype and the matrix-remodeling activity of cells treated with TGF-β1. Our data show a direct connection between the classical pro-fibrotic signaling driven by TGF-β1 and the mechanically activated pathways under the control of YAP/TAZ in cardiac remodeling. Treatment with the elective drug targeting YAP/TAZ is sufficient to override this cooperation with potential benefits for anti-fibrotic therapeutic applications. Funding Information: This work was supported by Institutional grants (Ricerca Corrente, 5 per 1000) issued by the Italian Ministry of Health to M.P. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: The use of human cardiac stromal cells was performed after authorization by the local ethical committee at Centro Cardiologico Monzino (approval date: 19 May 2012 and subsequent renewal on 16 May 2016) and have been performed in compliance with the Declaration of Helsinki. Patients signed an informed consent authorizing the donation of small fragments of cardiac tissue for research scopes.